Twist Bioscience (FRA:0ME) Cash, Cash Equivalents, Marketable Securities : €269.9 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience Cash, Cash Equivalents, Marketable Securities?

Twist Bioscience's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (€315.22 Mil) to Dec. 2023 (€285.32 Mil) but then stayed the same from Dec. 2023 (€285.32 Mil) to Mar. 2024 (€269.88 Mil).

Twist Bioscience's annual cash, cash equivalents, marketable securities increased from Sep. 2021 (€406.18 Mil) to Sep. 2022 (€510.02 Mil) but then declined from Sep. 2022 (€510.02 Mil) to Sep. 2023 (€315.22 Mil).

Twist Bioscience Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Twist Bioscience's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Cash, Cash Equivalents, Marketable Securities Chart

Twist Bioscience Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

125.40

246.21

406.18

510.02

315.22

Twist Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															362.07	329.65	315.22	285.32	269.88

Twist Bioscience Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Twist Bioscience (FRA:0ME) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Twist Bioscience Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Twist Bioscience (FRA:0ME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (FRA:0ME) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

TWST:USA 0ME:Germany

Address

681 Gateway Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.twistbioscience.com

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Twist Bioscience (FRA:0ME) Headlines

No Headlines